ImageneBio, Inc.
ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 12.5% and free cash flow grew 23.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IMA
ImageneBio, Inc. (IMA) EV/Sales
As of 16 October 2026, ImageneBio, Inc. (IMA) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from −15.8× (June 2021) to 40.9× (November 2021); the current reading is higher than 53% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −2.5× | — |
| FY2024 | 13.3× | — |
| FY2023 | −1.1× | — |
| FY2022 | 1.2× | (81.48%) |
| FY2021 | 6.4× | 1,083.29% |
| FY2020 | 0.5× | 0.00% |
| FY2019 | 0.5× | 0.00% |
| FY2018 | 0.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 1.5× | — |
| Sep 2024 | −3.6× | — |
| Dec 2023 | −1.1× | — |
| Sep 2023 | 4.1× | (56.50%) |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IBIO iBio, Inc. compare | −9.7× |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| IMA ImageneBio, Inc. | 2.5× |
| SER Serina Therapeutics, Inc. compare | 66.0× |
| INMB INmune Bio, Inc. compare | 210× |
| CLNN Clene Inc. compare | 239× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)